Spontaneous epigastric arterial bleeding associated with abciximab: Successful percutaneous treatment with coil gel-foam embolization

Journal of Invasive Cardiology

Volumn 14, Issue 11, 2002, Pages 692-693

  Cherukuri, Madhavagopal ^a   Pershad, Ashish ^a  

^a Heart and Vascular Center of Arizona   (United States)

Author keywords

Abciximab; Bleeding complication

Indexed keywords

ABCIXIMAB; GELFOAM; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; ARTIFICIAL EMBOLISM; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; FEMALE; GUIDE WIRE; HUMAN; INFERIOR EPIGASTRIC ARTERY; STOMACH HEMORRHAGE; TREATMENT OUTCOME; VASCULAR SURGERY; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; EPIGASTRIC ARTERY; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; EMBOLIZATION, THERAPEUTIC; EPIGASTRIC ARTERIES; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS;

EID: 0036827087     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
2. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc 2001;76:890-896.
3. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
4. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
5. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.